Aprea Therapeutics Files 8-K on Shareholder Vote Matters
Ticker: APRE · Form: 8-K · Filed: Jun 20, 2024 · CIK: 1781983
| Field | Detail |
|---|---|
| Company | Aprea Therapeutics, Inc. (APRE) |
| Form Type | 8-K |
| Filed Date | Jun 20, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-meeting
Related Tickers: APRE
TL;DR
APRE filed an 8-K for a shareholder vote. Details TBD.
AI Summary
Aprea Therapeutics, Inc. filed an 8-K on June 20, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain specific details about the vote outcomes or the proposals presented.
Why It Matters
This filing indicates that Aprea Therapeutics held a shareholder vote, which could have implications for the company's governance and future strategic decisions.
Risk Assessment
Risk Level: low — The filing is procedural and does not disclose new financial or operational risks.
Key Players & Entities
- Aprea Therapeutics, Inc. (company) — Registrant
- June 20, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Doylestown, PA (location) — Principal Executive Offices
FAQ
What specific matters were submitted for a vote by Aprea Therapeutics' security holders?
The filing states that it is a 'Submission of Matters to a Vote of Security Holders' but does not detail the specific proposals or resolutions presented to the shareholders.
When was the shareholder vote held or reported?
The report is dated June 20, 2024, and the 'Date of earliest event reported' is also June 20, 2024, indicating the vote matters were reported on this date.
What is the company's principal executive office address?
The principal executive offices are located at 3805 Old Easton Road, Doylestown, PA 18902.
What is Aprea Therapeutics' telephone number?
The registrant's telephone number, including area code, is (617) 463-9385.
What is the Commission File Number for Aprea Therapeutics?
The Commission File Number for Aprea Therapeutics, Inc. is 001-39069.
Filing Stats: 677 words · 3 min read · ~2 pages · Grade level 11.4 · Accepted 2024-06-20 16:15:25
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share APRE The NASDAQ Stock Mar
Filing Documents
- tm2417690d1_8k.htm (8-K) — 39KB
- 0001104659-24-073396.txt ( ) — 209KB
- apre-20240620.xsd (EX-101.SCH) — 3KB
- apre-20240620_lab.xml (EX-101.LAB) — 33KB
- apre-20240620_pre.xml (EX-101.PRE) — 22KB
- tm2417690d1_8k_htm.xml (XML) — 4KB
07
Item 5.07 Submission of Matters to a Vote of Security Holders. At the 2024 annual meeting of stockholders (the "Annual Meeting") of the Aprea Therapeutics, Inc. (the "Company") held on June 20, 2024, the following proposals were submitted to the stockholders of the Company: Proposal 1: A proposal to elect three Class II directors of the Company, Michael Grissinger, Gabriela Gruia, M.D. and Rifat Pamukcu, M.D., each to hold office until the 2027 Annual Meeting of Stockholders or until their successors shall have been duly elected and qualified. Proposal 2: A proposal to ratify the appointment of EisnerAmper LLP as the Company's independent registered public accounting firm for the 2024 fiscal year. For more information about the foregoing proposals, see the Company's definitive proxy statement on Schedule 14A filed with the United to vote at the Annual Meeting, 3,826,179 shares, or approximately 70.46%, were represented at the Annual Meeting in person or by proxy, constituting a quorum. The number of votes cast for, against or withheld, as well as abstentions and broker non-votes, if applicable, in respect of each such proposal is set forth below. Proposal 1: Election of Class II Directors. The Company's stockholders elected the following directors to serve as Class II directors until the 2027 Annual Meeting of Stockholders of the Company or until their successors are duly elected and qualified. The votes regarding the election of the directors were as follows: Director Votes For Votes Withheld Broker Non-Votes Michael Grissinger 3,051,902 54,753 719,524 Gabriela Gruia, M.D. 3,088,199 18,456 719,524 Rifat Pamukcu, M.D. 3,056,175 50,480 719,524 Proposal 2: Ratification of Appointment EisnerAmper LLP. The Company's stockholders ratified the appointment of EisnerAmper LLP as the Company's indepen
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 20, 2024 APREA THERAPEUTICS, INC. By: /s/ Oren Gilad Oren Gilad, Ph.D., President and Chief Executive Officer